Walgreens adds Take Care pharmacy at Electric Boat’s Groton shipyard
GROTON, Conn. Walgreens and General Dynamics Electric Boat have joined forces to open a second on-site pharmacy, this one at the company’s Groton, Conn., shipyard.
The new pharmacy will be managed by Walgreens’ Take Care Health Systems subsidiary, billed as “the largest and most comprehensive provider of convenient care clinics and worksite health-and-wellness centers in the country.” Take Care pharmacists at the newly opened site will provide prescriptions and pharmacy services to some 14,000 Electric Boat employees, retirees and their dependents enrolled in the company’s health plan.
The pharmacy will be open six days a week, according to an Electric Boat representative.
The opening of the new Groton pharmacy extends a health service alliance between Walgreens’ Take Care Health Systems and General Dynamics that began in 2007, when Take Care opened a center at Electric Boat’s Quonset Point facility in Rhode Island.
“Electric Boat currently recognizes the benefits associated with a worksite pharmacy and we’re excited to expand our partnership and collaborate on a second location,” said Peter Hotz, Walgreens’ divisional VP and president of Take Care Health Employer Solutions. “Worksite pharmacies enable ongoing communication and education between patients and pharmacists, create greater outcomes with medication adherence and demonstrate that when innovative companies like Electric Boat invest in employer health programs, patient results improve and savings are realized.”
Medco Health Solutions awarded by The Joint Commission
FRANKLIN LAKES, N.J, Pharmacy benefit manager Medco Health Solutions has received a nod for its home care and pharmacy dispensing services from a healthcare standards and accrediting body, Medco said Tuesday.
The PBM said it received the Gold Seal of Approval from The Joint Commission. The recognition applies to services offered to clients and health plan members by Medco’s dispensing and call center pharmacies, and Medco said the approval places it among the leading organizations in its category. The organization’s accreditation process includes a review of 129 standards across 13 areas of focus, including treatment and services, rights and ethics, medication management and information management.
“This independent review validates the progress we have made in driving ever-higher standards in clinical excellence as we focus on closing the gaps in care for patients with chronic and complex conditions – patients who account for 96% of all drug spending and 75% of all medical costs,” Medco president and COO Kenny Klepper said. “The fact that in our reaccreditation The Joint Commission consistently found a high level of service across so many facilities speaks to the diligence and professionalism of Medco people at every level across our company.”
Astellas completes acquisition of OSI
TOKYO Japanese drug maker Astellas Pharma has completed its acquisition of OSI Pharmaceuticals, Astellas said Tuesday.
The $4 billion acquisition, announced in May, gives Astellas access to such drugs as the cancer drug Tarceva (erlotinib), which OSI co-markets with Roche division Genentech. OSI has lately been enrolling subjects for a late-stage clinical trial of OSI-906, a treatment for patients with adrenocortical carcinoma, a rare cancer of the adrenal gland, whose disease has spread to other parts of the body.
OSI will become a wholly owned subsidiary of Astellas through Astellas US Holding, a holding company.